Skip to content
Menu

Aura Biosciences, Inc. AURA

Full chart Compare
Set alert

Price alert · AURA

All alert types
6.98 USD -0.16 (-2.24%)

Regular-session close

6.98 0.00 0.00%

After hours · Nov 19, 4:01 PM ET

6.83 Day range 7.24
4.73 52-week range 9.54
YTD
+28.07%
1 year
+29.26%

5D +0.47 (+7.08%)

77.508MonTueWedThuFri7.11
Market cap
726.44M
EPS (ttm)
-1.55
Shares out
49.95M
Forward P/E
-4.05
YTD return
+28.07%
1-year return
+29.26%
50-day average
9.67
200-day average
8.40
Enterprise value
254.31M
Volume
495.31K
Avg volume
844.99K
Open
7.11
Previous close
7.14
Day's range
6.83 – 7.24
52-week range
4.73 – 9.54
Beta
0.33
Analysts
Strong Buy
Price target
21.83 (+212.8%)

Key statistics

Price / book
2.35
Free cash flow
-47.35M
Total cash
174.38M
Total debt
19.08M
Return on equity
-50.99%
Short % of float
2.80%

Fundamental scorecard

5 of 25 checks passed on AURA’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
AURA Revenue — quarterly 0
AURA Net income — quarterly -32.07M
AURA EPS — quarterly -0.29

Earnings

AURA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 12, 2024Sep 1, 2024-0.44-0.42+0.02+4.55%
Aug 8, 2024Jun 1, 2024-0.45———
Aug 8, 2024Jun 1, 2024-0.45-0.41+0.04+8.89%
May 9, 2024Mar 1, 2024-0.51-0.40+0.11+21.57%
May 9, 2024Mar 1, 2024-0.51———
Mar 27, 2024Dec 1, 2023-0.39———

Upgrades / downgrades

AURA analyst upgrades and downgrades
DateFirmActionFromTo
Nov 14, 2024HC Wainwright & Co.reitBuyBuy
Oct 18, 2024ScotiabankmainSector OutperformSector Outperform
Oct 18, 2024BTIGmainBuyBuy
Oct 18, 2024HC Wainwright & Co.mainBuyBuy
Sep 13, 2024JMP SecuritiesmainMarket OutperformMarket Outperform
Sep 13, 2024HC Wainwright & Co.reitBuyBuy

About Aura Biosciences, Inc.

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmette–guérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on AURA — it syncs with the Stock Master app.

Insider holders

AURA insider holders
InsiderRelationLatest transactionDateShares held
DE LOS PINOS ELISABETChief Executive OfficerSaleOct 28, 2024452,059
ELAZZOUZI AMYOfficerSaleOct 28, 202439,443
FEDER JULIE BChief Financial OfficerSaleOct 17, 2024134,276
HOPKINS JANET JILLOfficerSaleNov 17, 2024151,693
JOHNSON DAVID MICHAELDirectorStock Award(Grant)Jun 19, 2024435,839
KILROY CONORGeneral CounselStock Award(Grant)Apr 1, 202496,000

Institution ownership

AURA institution ownership
Holder% heldSharesValueReported
Matrix Capital Management13.86%6,922,87056.98MSep 29, 2024
Eventide Asset Management LLC11.62%5,802,68247.76MSep 29, 2024
Adage Capital Partners GP L.L.C.9.77%4,881,12540.17MSep 29, 2024
Blackrock Inc.6.33%3,160,41426.01MSep 29, 2024
Medicxi Ventures Management (Jersey) Ltd6.09%3,039,89225.02MSep 29, 2024
Vanguard Group Inc3.61%1,805,43414.86MSep 29, 2024

Fund ownership

AURA fund ownership
Holder% heldSharesValueReported
Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund11.62%5,802,68247.76MSep 29, 2024
iShares Russell 2000 ETF2.27%1,133,2249.33MOct 30, 2024
Vanguard Total Stock Market Index Fund1.70%848,9996.99MSep 29, 2024
Vanguard Extended Market Index Fund1.27%633,9675.22MSep 29, 2024
Franklin Strategic Series-Franklin Biotechnology Discove1.14%568,4714.68MJul 30, 2024
Fidelity Small Cap Index Fund0.95%473,9643.90MAug 30, 2024